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Ken Okumura, MD, PhD,‡ Takeshi Yamashita, MD, PhD,§ and Hideki Origasa, PhD,‖
on behalf of the J-RHYTHM Registry Investigators
Background: Prior ischemic stroke or transient ischemic attack (TIA) is a high risk
for thromboembolism in patients with nonvalvular atrial fibrillation (NVAF). To
clarify rates of thromboembolic and hemorrhagic events, and target intensities of
warfarin for secondary prevention, a subanalysis was performed using data from
the J-RHYTHM Registry. Methods: Of 7937 outpatients with atrial fibrillation, 7406
with NVAF (men 70.8%, 69.8 ± 10.0 years) were followed for 2 years or until an
event occurred. Event rates and effect of warfarin were compared between pa-
tients with (secondary prevention) and without (primary prevention) prior stroke/TIA.
Results: Prevalence of male sex, diabetes mellitus, and mean age were higher in
the secondary prevention group, showing a higher CHADS2 (congestive heart failure,
hypertension, age 75 years or older, diabetes mellitus, and history of stroke or
TIA) score than the primary prevention group (3.5 ± 1.0 versus 1.4 ± 1.0, P < .001).
In the secondary prevention group, 93.4% of patients received warfarin and their
time in therapeutic range was 62.8%. During follow-up, thromboembolism oc-
curred more frequently in the secondary than in the primary prevention
group (2.8% versus 1.5%, P = .004), especially in patients without warfarin. Major
hemorrhage also occurred more frequently in the secondary prevention group
(3.0% versus 1.7%, P = .006). Compared with patients not taking warfarin, com-
bined rates of both events were lower at an international normalized ratio
(INR) of 1.6-2.59 in patients taking warfarin in the secondary as well as in the
primary prevention groups. Conclusions: Both thromboembolism and
major hemorrhage occurred more frequently in NVAF patients with prior ischemic
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stroke/TIA. Target INR should be 1.6-2.59 for secondary as well as primary pre-
vention of thromboembolism in Japanese NVAF patients. Key Words: Atrial
fibrillation—anticoagulation—warfarin—stroke—secondary prevention.
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Introduction
Atrial fibrillation (AF) is the most common sustained
arrhythmia and is a major risk factor for cardiogenic
embolism.1,2 CHADS23 (congestive heart failure, hyper-
tension, age 75 years or older, diabetes mellitus, and history
of stroke or transient ischemic attack (TIA)) or CHA2DS2-
VASc scores4 are widely used for risk stratification of
ischemic stroke and systemic embolism in patients with
nonvalvular atrial fibrillation (NVAF). A history of isch-
emic stroke or TIA carries a stronger risk for ischemic
stroke than other components of these scores.3,4 Once pa-
tients suffer from cardiogenic embolism, their condition
is mostly severe, and mortality can be higher as com-
pared with other types of ischemic stroke.5 In addition,
cardiogenic embolism had a higher 10-year recurrence rate
(75.2%) after the first event in the Hisayama study.6 There-
fore, prophylaxis with anticoagulation therapy is crucial
for reducing AF-related ischemic stroke in patients with
a history of stroke or TIA (stroke/TIA). Oral anticoagu-
lation therapy with vitamin K antagonists, mainly warfarin,
can reduce the risk of AF-related ischemic stroke by
60%-70%.7,8 However, information regarding the inci-
dence of thromboembolic and hemorrhagic events in
Japanese NVAF patients with a history of ischemic stroke/
TIA is still limited.9,10 Therefore, we investigated the
incidence of thromboembolic and hemorrhagic events in
patients with and without a history of ischemic stroke/
TIA, using a post hoc analysis of the J-RHYTHM
Registry.11-13 Additionally, optimal anticoagulation inten-
sities of warfarin for patients with a history of ischemic
stroke/TIA were determined, although these had previously
been determined using a small number of Japanese
patients.10 Because a target international normalized ratio
(INR) of prothrombin time is different between NAVF pa-
tients aged younger than 70 and 70 years or older in the
current Japanese guidelines,14 we also investigated event
rates in both age groups of younger than 70 and 70 years
or older.
Methods
Study Design of the J-RHYTHM Registry
The J-RHYTHM Registry was a prospective, observa-
tional nationwide study. Study design and baseline
characteristics have been reported in detail elsewhere.11,12
Briefly, the subjects were a consecutive series of outpa-
tients with AF of any type, regardless of the use of
antithrombotic drugs. Antithrombotic drugs and dosages
were selected at the discretion of the treating cardiolo-
gists. Because no nonvitamin K antagonist oral
anticoagulant (NOAC) was available when this registry
was carried out in 2009, all anticoagulation therapies
were performed with warfarin in this study. Patients
with valvular AF, including mitral stenosis and mechan-
ical prosthetic valves,15 were excluded from this subanalysis.
Follow-Up and Definition of Endpoints
The patients were followed for 2 years, or until an
endpoint, whichever occurred first. The thromboem-
bolic endpoints consisted of symptomatic ischemic stroke,
TIA, and systemic embolism. Major hemorrhage as the
safety endpoint included intracranial hemorrhage, gas-
trointestinal hemorrhage, and others requiring
hospitalization. All-cause mortality and cardiovascular mor-
tality were also determined. If any event occurred during
the follow-up period, the final clinical data, including INR
at the time closest to the event, were collected.11 The di-
agnostic criteria for each event have been described
elsewhere.11,12
Classification of Patients
Patients were divided into 2 groups, that is, the
“primary” and “secondary” prevention groups, accord-
ing to the history of ischemic stroke/TIA, and were divided
further into 2 age groups of younger than 70 and 70 years
or older. In addition, patients receiving warfarin were
divided into 5 subgroups according to their INR (<1.6,
1.6-1.99, 2.0-2.59, 2.6-2.99, and ≥3.0). Correlation of end-
points with anticoagulation intensities was analyzed with
INR at the time of events or at the end of follow-up. The
time in therapeutic range (TTR) was determined with the
method of Rosendaal et al.16 For this determination,
the target INR level was set at 1.6-2.6 for patients aged
70 years or older, and at 2.0-3.0 for patients aged younger
than 70 years, following the Japanese guidelines.14
Statistical Analysis
Data are presented as mean ± standard deviation or
median, if necessary. The statistical significance of dif-
ferences in the mean values was analyzed using Student’s
t-test or analysis of variance, in the median values using
the Mann–Whitney U-test or Kruskal–Wallis test, as ap-
propriate. Frequencies of parameters or events were
compared using the chi-square test or Fisher’s exact test,
as appropriate. Event-free rates of thromboembolism and
major hemorrhage between the primary and secondary
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prevention groups were compared using the Kaplan–
Meier method and log-rank test. A Cox proportional hazard
model was used to examine whether a history of stroke/
TIA was an independent risk factor for the events in a
crude model (Model 1) and after adjustment for con-
founding factors, including the other components of
CHADS2 (Model 2) and CHA2DS2-VASc scores (addition-
ally, vascular disease [coronary artery disease], age 65-
74 years, and female sex: Model 3), and warfarin and
antiplatelet use (Model 4). To clarify the optimal INR level,
a multivariate logistic regression analysis was per-
formed. Two-sided P values less than .05 were considered
to be statistically significant. All statistical analyses were
performed with the IBM SPSS Statistics version 23.0 (IBM
Corporation, Somers, NY).
Results
Of the 7937 patients with AF who had been enrolled
in the J-RHYTHM Registry, 421 patients were excluded
because they had valvular AF. Of the remaining 7516
patients with NVAF, 110 (1.5%) were lost to follow-up.
Therefore, a total of 7406 patients with NVAF, that is,
6384 patients without and 1022 patients with a history
of ischemic stroke/TIA, were eligible for the present
analyses.
Baseline Characteristics and the Status of
Antithrombotic Therapy
Baseline clinical characteristics and antithrombotic therapy
at the time of enrollment are summarized in Tables 1 and
Table 1. Baseline characteristics of patients
Characteristics Overall Primary prevention group Secondary prevention group P value*
Number of patients 7406 6384 (86.2) 1022 (13.8)
Age (years) 69.8 ± 10.0 69.3 ± 10.1 72.3 ± 8.8 <.001
Sex, male 5241 (70.8) 4479 (70.2) 762 (74.6) .005
Type of atrial fibrillation
Paroxysmal 2835 (38.3) 2497 (39.1) 338 (33.1)
Persistent 1081 (14.6) 944 (14.8) 137 (13.4) <.001
Permanent 3490 (47.1) 2943 (46.1) 547 (53.5)
Comorbidities
Coronary artery disease 781 (10.5) 647 (10.1) 134 (13.1) .005
Cardiomyopathy 634 (8.6) 556 (8.7) 78 (7.6) .279
HCM 264 (3.6) 217 (3.4) 47 (4.6) .065
DCM 370 (5.0) 339 (5.3) 31 (3.0) .002
Congenital heart disease 96 (1.3) 88 (1.4) 8 (.8) .157
COPD 131 (1.8) 107 (1.7) 24 (2.3) .166
Hyperthyroidism 131 (1.8) 119 (1.9) 12 (1.2) .154
Risk factors for stroke
Heart failure 2055 (27.7) 1779 (27.9) 276 (27.0) .594
Hypertension 4477 (60.5) 3835 (60.1) 642 (62.8) .103
Age (≥75 years) 2565 (34.6) 2125 (33.3) 440 (43.1) <.001
Diabetes mellitus 1359 (18.3) 1140 (17.9) 219 (21.4) .007
Stroke/TIA 1022 (13.8) 0 (.0) 1022 (100.0) <.001
CHADS2 score
0 1157 (15.6) 1157 (18.1) 0 (.0)
1 2512 (33.9) 2512 (39.3) 0 (.0)
2 2056 (27.8) 1891 (29.6) 165 (16.1)
3 1059 (14.3) 711 (11.1) 348 (34.1) <.001
4 436 (5.9) 113 (1.8) 323 (31.6)
5 161 (2.2) 0 (.0) 161 (15.8)
6 25 (.3) 0 (.0) 25 (2.4)
Mean 1.7 ± 1.2 1.4 ± 1.0 3.5 ± 1.0 <.001
Median 2 [1-2] 1 [1-2] 3 [3-4] <.001
Abbreviations: CHADS2, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, and history of stroke or TIA;
COPD, chronic obstructive pulmonary disease; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; SD, standard deviation;
TIA, transient ischemic attack.
Data are number of patients (%), mean ± SD, or median [interquartile range].
*Comparison between primary and secondary prevention groups.
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2, respectively. Mean age and the prevalence of male sex,
diabetes mellitus, and coronary artery disease were higher
in the secondary than in the primary prevention group.
It was a matter of course that the CHADS2 score was 2
or higher in all patients of the secondary prevention group,
giving a higher mean CHADS2 score of 3.5 ± 1.0, as com-
pared with the primary prevention group (Table 1). The
frequency of warfarin use as well as antiplatelet drugs
was higher in the secondary than in the primary pre-
vention group (Table 2). Mean INR and TTR were slightly
but significantly higher in the secondary than in the
primary prevention group (Table 2).
Event Rates and a History of Stroke/TIA
During the 2-year follow-up period, thromboembolic
events occurred in 126 patients (1.7%), major hemor-
rhage in 140 (1.9%), and all-cause death in 195 (2.6%),
including cardiovascular death in 68 (.9%). The overall
incidence of thromboembolism was significantly higher
in the secondary than in the primary prevention group
(2.8% versus 1.5%, P = .004). The incidence rate of major
hemorrhage was also higher in the secondary than in the
primary prevention group (3.0% versus 1.7%, P = .006).
All-cause mortality was higher in the secondary than in
the primary prevention group (3.9% versus 2.4%, P = .008),
whereas cardiovascular mortality was comparable between
the groups (1.0% versus .9%, P = .967). The Kaplan–
Meier curves for endpoints are shown in Figure 1. Event-
free rates of thromboembolism, major hemorrhage, and
all-cause death in the secondary prevention group were
significantly lower than those in the primary preven-
tion group (P = .002, P = .003, and P = .004 by log-tank
test, respectively; Fig 1, A-C). Cardiovascular mortality
was comparable between the groups (Fig 1, D). As a whole
group, hazard ratios (HRs) of a prior ischemic stroke/
TIA for thromboembolism remained significantly high even
in the most critical adjusting model (HR 1.82, P = .006
in Model 4). Although the HR for major hemorrhage in
Model 4 did not reach statistical significance (HR 1.49,
P = .055), HRs for combined events of thromboembo-
lism plus major hemorrhage were consistently high even
after adjustment for multiple confounding factors (HR
1.64, P = .001 in Model 4; Table 3). The HRs for all-
cause death were significantly high in only the crude model
(Model 1) and after adjustment for CHADS2 score (Model
2), whereas those for cardiovascular death were similar
in any model. These results indicated that a history of
ischemic stroke/TIA was an independent risk factor for
thromboembolism and for combined events of thrombo-
embolism and major hemorrhage (Table 3).
Event Rates and Warfarin Use
The characteristics of patients in the nonwarfarin and
warfarin groups and 5 INR subgroups are summarized
in Table 4. Twenty patients, including 18 without infor-
mation on warfarin use and 2 lacking INR values at the
end of follow-up, were excluded. Consequently, the re-
maining 7386 patients were used for post hoc analyses
requiring INR values at the end of follow-up. In the primary
prevention group, prevalence of all components of CHADS2
score except for prior stroke/TIA in patients on warfarin
was higher than that in the nonwarfarin group, resulting
in a higher CHADS2 score in patients on warfarin. By
contrast, in the secondary prevention group, prevalence
of patients aged 75 years or older and those with dia-
betes mellitus in the nonwarfarin group was higher than
Table 2. Antithrombotic therapy at the time of enrollment
Antithrombotic therapy Overall Primary prevention group Secondary prevention group P value*
Warfarin 6404 (86.5) 5449 (85.4) 955 (93.4) <.001
Dosage (mg/day) 2.9 ± 1.2 2.9 ± 1.2 2.8 ± 1.1 .016
INR
<1.6 1670 (26.1) 1477 (27.1) 193 (20.2)
1.6-1.99 2348 (36.7) 1985 (36.4) 363 (38.0)
2.0-2.59 1854 (29.0) 1552 (28.5) 302 (31.6) <.001
2.6-2.99 363 (5.7) 292 (5.4) 71 (7.4)
≥3.0 169 (2.6) 143 (2.6) 26 (2.7)
Mean 1.91 ± .49 1.90 ± .49 1.97 ± .48 <.001
TTR** (%) 59.3 ± 29.2 58.7 ± 29.3 62.8 ± 28.1 <.001
(n = 6064) (n = 5166) (n = 898)
Any antiplatelet 1937 (26.2) 1550 (24.3) 387 (37.9) <.001
Aspirin 1675 (22.6) 1362 (21.3) 313 (30.6) <.001
Others 433 (5.8) 321 (5.0) 112 (11.0) <.001
Warfarin + antiplatelet 1358 (18.3) 1027 (16.1) 331 (32.4) <.001
Abbreviations: INR, international normalized ratio of prothrombin time; SD, standard deviation; TTR, time in therapeutic range.
Data are number of patients (%) or mean ± SD.
*Comparison between primary and secondary prevention groups.
**Target INR, 2.0-3.0 (<70 years) or 1.6-2.6 (≥70 years).
588 E. KODANI ET AL.
Figure 1. Event-free curves for thromboembolism (A), major hemorrhage (B), all-cause death (C), and cardiovascular death (D) in the primary and sec-
ondary prevention groups using the Kaplan–Meier method. Additional boxes show the magnified event-free curves with 10-fold scale. P values: comparison
between the primary and secondary groups by log-rank test.
Table 3. Risk of a history of ischemic stroke/TIA for events (Cox proportional hazards analysis)
Events
Model 1 Model 2 Model 3 Model 4
HR 95% CI P HR 95% CI P HR 95% CI P HR 95% CI P
Thromboembolism 1.92 1.27-2.91 .002 1.75 1.16-2.66 .008 1.72 1.13-2.61 .011 1.82 1.19-2.79 .006
Major hemorrhage 1.82 1.22-2.72 .003 1.67 1.12-2.49 .012 1.58 1.06-2.37 .025 1.49 .99-2.23 .055
Thromboembolism + major
hemorrhage
1.87 1.40-2.49 <.001 1.71 1.28-2.28 <.001 1.65 1.23-2.20 .001 1.64 1.23-2.20 .001
All-cause death 1.66 1.17-2.36 .004 1.49 1.05-2.11 .026 1.39 .98-1.97 .065 1.41 .99-2.01 .055
Cardiovascular death 1.11 .57-2.12 .755 1.03 .52-2.02 .939 .99 .50-1.94 .966 .95 .48-1.88 .888
Abbreviations: CI, confidence interval; HR, hazard ratio; TIA, transient ischemic attack.
Model 1: unadjusted (crude).
Model 2: adjusted for the other components of CHADS2 score (congestive heart failure, hypertension, age 75 years or older, and diabetes
mellitus).
Model 3: adjusted for the other components of CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years or older, dia-
betes mellitus, vascular disease [coronary artery disease], age 65-74 years, and female sex).
Model 4: adjusted for the other components of CHA2DS2-VASc score, warfarin use, and antiplatelet use.
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Table 4. Characteristics of nonwarfarin and warfarin groups, and 5 INR subgroups
Characteristics Nonwarfarin
Warfarin
P value**All
INR level*
<1.6 1.6-1.99 2.0-2.59 2.6-2.99 ≥3.0
Primary prevention group
Number of patients 1023 5343 1193 1898 1694 331 227
Age (years) 66.9 ± 12.0 69.8 ± 9.6 70.6 ± 9.9 69.7 ± 9.4 69.3 ± 9.7 69.8 ± 9.6 70.9 ± 9.0 <.001
Sex, male 723 (70.7) 3745 (70.1) 798 (66.9) 1334 (70.3) 1222 (72.1) 236 (71.3) 155 (68.3) <.001
Risk factors for stroke
Heart failure 186 (18.2) 1587 (29.7) 395 (33.1) 501 (26.4) 510 (30.1) 103 (31.1) 78 (34.4) <.001
Hypertension 549 (53.7) 3275 (61.3) 717 (60.1) 1151 (60.6) 1038 (61.3) 222 (67.1) 147 (64.8) <.001
Age (≥75 years) 280 (27.4) 1841 (34.5) 466 (39.1) 637 (33.6) 555 (32.8) 100 (30.2) 83 (36.6) <.001
Diabetes mellitus 128 (12.5) 1009 (18.9) 245 (20.5) 348 (18.3) 310 (18.3) 63 (19.0) 43 (18.9) <.001
Stroke/TIA 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) 0 (.0) –
CHADS2 score
Mean 1.1 ± 1.0 1.4 ± 1.0 1.5 ± 1.0 1.4 ± .9 1.4 ± .9 1.5 ± .9 1.6 ± 1.0 <.001
Median 1 [0-2] 1 [1-2] 1 [1-2] 1 [1-2] 1 [1-2] 1 [1-2] 2 [1-2] <.001
Secondary prevention group
Number of patients 103 917 196 333 293 54 41
Age (years) 74.7 ± 9.0 72.1 ± 8.7 72.2 ± 9.9 72.2 ± 8.9 71.6 ± 8.3 72.1 ± 8.7 73.2 ± 8.6 .083
Sex, male 77 (74.8) 684 (74.6) 132 (67.3) 251 (75.4) 236 (80.5) 36 (66.7) 29 (70.7) <.001
Risk factors for stroke
Heart failure 32 (31.1) 243 (26.5) 55 (28.1) 87 (26.1) 70 (23.9) 18 (33.3) 13 (31.7) .534
Hypertension 68 (66.0) 573 (62.5) 111 (56.6) 222 (66.7) 182 (62.1) 34 (63.0) 24 (58.5) .291
Age (≥75 years) 60 (58.3) 379 (41.3) 83 (42.3) 142 (42.6) 111 (37.9) 11 (20.4) 20 (48.8) <.001
Diabetes mellitus 26 (25.2) 192 (20.9) 36 (18.4) 79 (23.7) 57 (19.5) 23 (42.6) 9 (22.0) .005
Stroke/TIA 103 (100.0) 917 (100.0) 196 (100.0) 333 (100.0) 293 (100.0) 54 (100.0) 41 (100.0) –
CHADS2 score
Mean 3.8 ± 1.0 3.5 ± 1.0 3.5 ± 1.0 3.6 ± 1.0 3.4 ± 1.0 3.6 ± 1.1 3.6 ± 1.0 .014
Median 4 [3-5] 3 [3-4] 3 [3-4] 4 [3-4] 3 [3-4] 4 [3-4] 4 [3-4] .025
Abbreviations: CHADS2, congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, and history of stroke or TIA; INR, international normalized ratio of prothrombin time;
SD, standard deviation; TIA, transient ischemic attack.
Data are number of patients (%), mean ± SD, or median [interquartile range].
*At the time of events or at the end of follow-up.
**Comparison among 6 groups (nonwarfarin group and 5 INR subgroups) in patients receiving warfarin.
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that in patients on warfarin, resulting in a higher CHADS2
score in the nonwarfarin group than in patients on war-
farin (Table 4). Rates of thromboembolism and all-cause
death were significantly higher in the secondary than in
the primary prevention group (8.7% versus 2.5%, P = .002;
and 17.5% versus 5.8%, P < .001, respectively), when war-
farin was not given (Table 5). However, the rate of
thromboembolic events was significantly lower in the war-
farin group than in the nonwarfarin group, especially in
the secondary prevention group (Fig 2, A). By contrast,
rates of major hemorrhage in patients with and without
warfarin were not different in either the primary or sec-
ondary prevention group (Fig 2, B). All-cause and
cardiovascular mortality showed similar trends to that
of thromboembolism (Fig 2, C,D).
In patients who received warfarin, cerebral infarction oc-
curred eventually in 54 (1.0%/2 years) and 19 (2.1%/2 years)
patients in the primary and secondary prevention groups,
respectively (Table 5), including typical cardiogenic em-
bolism in 18 and 7, atherothrombotic stroke in 5 and 2,
lacunar infarction in 3 and 1, and undetermined in others.
Event Rates in INR Subgroups
Incidence rates of thromboembolism for both the primary
and secondary prevention groups showed an obvious de-
creasing trend among the nonwarfarin group and 5 INR
subgroups of patients receiving warfarin (P < .001 for trend
in both groups, Table 5). Rates of major hemorrhage for
both prevention groups also showed an apparent in-
creasing trend among the nonwarfarin group and 5 INR
subgroups in patients receiving warfarin (P < .001 and
P = .009 for trend, respectively; Table 5). Consequently,
the combined rates of thromboembolic and major
Figure 2. Two-year incidence of thromboembo-
lism (A), major hemorrhage (B), all-cause death
(C), and cardiovascular death (D). P values: com-
parison between patients with and without warfarin
in each group.
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Table 5. Incidence rates of events during the 2-year follow-up period
Events Nonwarfarin
Warfarin
P value**All
INR level*
<1.6 1.6-1.99 2.0-2.59 2.6-2.99 ≥3.0
Primary prevention group
Number of patients 1023 5343 1193 1898 1694 331 227
Thromboembolism 26 (2.5%) 71 (1.3%) 37 (3.1%) 17 (.9%) 10 (.6%) 4 (1.2%) 3 (1.3%) <.001†
Cerebral infarction 22 54 26 15 6 4 3
TIA 2 6 2 1 3 0 0
Systemic embolism 2 11 9 1 1 0 0
Major hemorrhage 12 (1.2%) 97 (1.8%) 11 (.9%) 17 (.9%) 26 (1.5%) 8 (2.4%) 35 (15.4%) <.001†
Intracranial 4 28 5 6 9 2 6
Gastrointestinal 3 36 3 6 9 3 15
Others 5 33 3 5 8 3 14
Thromboembolism + major
hemorrhage
38 (3.7%) 168 (3.1%) 48 (4.0%) 34 (1.8%) 36 (2.1%) 12 (3.6%) 38 (16.7%) <.001
All-cause death 59 (5.8%) 96 (1.8%) 24 (2.0%) 34 (1.8%) 19 (1.1%) 7 (2.1%) 12 (5.3%) <.001
Cardiovascular death 17 (1.7%) 41 (.8%) 21 (.9%) 14 (.7%) 10 (.6%) 2 (.6%) 4 (1.8%) .049
Secondary prevention group
Number of patients 103 917 196 333 293 54 41
Thromboembolism 9 (8.7%) 20 (2.2%) 11 (5.6%) 6 (1.8%) 2 (.7%) 1 (1.9%) 0 (.0%) <.001†
Cerebral infarction 9 19 11 5 2 1 0
TIA 0 1 0 1 0 0 0
Systemic embolism 0 0 0 0 0 0 0
Major hemorrhage 2 (1.9%) 29 (3.2%) 6 (3.1%) 5 (1.5%) 9 (3.1%) 5 (9.3%) 4 (9.8%) .009†
Intracranial 0 18 2 4 7 3 2
Gastrointestinal 1 7 3 1 0 2 1
Others 1 4 1 0 2 0 1
Thromboembolism + major
hemorrhage
11 (10.7%) 49 (5.3%) 17 (8.7%) 11 (3.3%) 11 (3.8%) 6 (11.1%) 4 (9.8%) <.001
All-cause death 18 (17.5%) 21 (2.3%) 5 (2.6%) 3 (.9%) 7 (2.4%) 1 (1.9%) 5 (12.2%) <.001
Cardiovascular death 5 (4.9%) 5 (.5%) 0 (.0%) 2 (.6%) 1 (.3%) 0 (.0%) 2 (4.9%) <.001
Abbreviations: INR, international normalized ratio of prothrombin time; TIA, transient ischemic attack.
Data are number of patients (%).
*At the time of events or at the end of follow-up.
**Comparison among 6 groups (nonwarfarin group and 5 INR subgroups) in patients receiving warfarin (chi-square test).
†For trend.
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hemorrhagic events were lower at INR levels of 1.6-2.59
in both prevention groups (Table 5). All-cause mortality
was lower in patients on warfarin than in those without
warfarin for both prevention groups (Table 5). This trend
was negated at INR levels of 3.0 or higher in both pre-
vention groups. Odds ratios (ORs) for thromboembolism
were significantly lower in INR subgroups of 1.6-1.99 and
2.0-2.59 than in the nonwarfarin group, even after ad-
justment for confounding factors, in both the primary and
secondary prevention groups (Table 6). By contrast, the
significance of ORs for major hemorrhage in INR sub-
groups disappeared after adjustment for confounding
factors in the secondary prevention group (Table 6). Con-
sequently, ORs for thromboembolism plus major
hemorrhage were significantly lower in INR subgroups
of 1.6-2.59 than in the nonwarfarin group, even after
adjustment for confounding factors, in both the primary
and secondary prevention groups (Table 6). ORs for all-
cause death were significantly lower in INR subgroups
of lower than 3.0 in both prevention groups (Table 6).
Event Rates in Age Groups
When the same analyses were performed in 2 age groups
of younger than 70 and 70 years or older, rates of throm-
boembolism were significantly lower in patients taking
warfarin than in the nonwarfarin group among patients
aged 70 years or older in both the primary and second-
ary groups (Fig 3, A). By contrast, the differences did not
reach a significant level even in the secondary group, al-
though rates of major hemorrhage appeared to be slightly
higher in patients on warfarin in all groups (Fig 3, B).
Figure 3. Two-year incidence of thromboembo-
lism (A), major hemorrhage (B), all-cause death
(C), and cardiovascular death (D) in each age
group. P values: comparison between patients with
and without warfarin in each group.
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Table 6. Odds ratios for events in each INR subgroup
Events
Nonwarfarin
(reference)
Warfarin
P value
INR level*
<1.6 1.6-1.99 2.0-2.59 2.6-2.99 ≥3.0
Primary prevention group
Thromboembolism 1.00 1.04 (.61-1.78) .31 (.16-.58) .21 (.10-.43) .43 (.15-1.25) .44 (.13-1.49) <.001
Major hemorrhage 1.00 .69 (.30-1.60) .70 (.33-1.50) 1.21 (.60-2.44) 1.90 (.76-4.76) 13.90 (6.95-27.78) <.001
Thromboembolism + major hemorrhage 1.00 .91 (.58-1.43) .42 (.26-.68) .50 (.31-.80) .87 (.44-1.69) 4.47 (2.73-7.33) <.001
All-cause death 1.00 .21 (.12-.35) .22 (.14-.35) .13 (.07-.22) .26 (.11-.59) .55 (.28-1.08) <.001
Cardiovascular death 1.00 .35 (.16-.78) .35 (.17-.73) .26 (.11-.58) .27 (.06-1.22) .65 (.21-2.03) <.001
Secondary prevention group
Thromboembolism 1.00 .75 (.29-1.96) .23 (.08-.70) .08 (.02-.41) .23 (.03-1.96) 0 .005
Major hemorrhage 1.00 1.65 (.34-8.02) .76 (.14-4.12) 1.65 (.34-8.02) 5.30 (.96-29.28) 5.64 (.96-33.08) .157
Thromboembolism + major hemorrhage 1.00 .90 (.39-2.01) .32 (.13-.78) .36 (.15-.89) 1.17 (.40-3.47) 1.02 (.30-3.49) .044
All-cause death 1.00 .11 (.04-.35) .04 (.01-.14) .11 (.04-.29) .10 (.01-.79) .66 (.20-2.14) <.001
Cardiovascular death 1.00 0 .18 (.03-1.09) .11 (.01-1.02) 0 1.27 (.21-7.79) .001
Abbreviations: INR, international normalized ratio of prothrombin time.
Data are odds ratios (95% confidence interval) adjusted for the components of CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, vascular
disease [coronary artery disease], age 65-74 years, and female sex) and antiplatelet use, using the nonwarfarin group as a reference.
*At the time of events or at the end of follow-up.
594
E
.
K
O
D
A
N
I
E
T
A
L.
All-cause death and cardiovascular mortality in both age
groups showed similar trends to that of thromboembo-
lism (Fig 3, C,D). Event rates among the nonwarfarin group
and 5 INR subgroups are summarized in Table 7. There
were significant trends in rates of thromboembolism and
major hemorrhage in all age groups, except for major hem-
orrhage in patients aged younger than 70 years in the
secondary group (Table 7).
ORs for events in each age group and INR subgroup
are summarized in Table 8. In patients aged younger
than 70 years in the primary prevention group, ORs for
thromboembolism, combined events of thromboembolism
plus major hemorrhage, and all-cause death were sig-
nificantly lower in INR subgroups of 1.6-1.99 and 2.0-2.59,
whereas those for major hemorrhage were significantly
higher in the INR subgroups of 2.6-3.0 and 3.0 or
higher, as compared with the nonwarfarin group (Table 8,
A). In patients aged younger than 70 years in the
secondary prevention group, OR for all-cause death
was significantly lower in only the INR subgroup of
2.0-2.59 because the numbers of patients and events
were small (Table 8, B). In patients aged 70 years or
older in both the primary and secondary prevention
groups, ORs for thromboembolism were significantly
lower in the INR subgroups of 1.6-1.99 and 2.0-2.59,
and those for combined events of thromboembolism
plus major hemorrhage were significantly lower in the
INR subgroup of 1.6-1.99 (Table 8, A,B).
Discussion
There were major findings in the present study. First,
as expected, patients with a history of ischemic stroke/
TIA were characterized as a high-risk population, with
a CHADS2 score of 3.5 ± 1.0. Second, warfarin was pre-
scribed in approximately 93%, and the TTR, based on the
Japanese guidelines,14 was 62.8% in the secondary pre-
vention group. This indicates that anticoagulation therapy
was performed frequently, and the quality of warfarin
therapy seemed acceptable among NVAF patients with
a history of ischemic stroke/TIA in Japan.17 However, rates
of both thromboembolism and major hemorrhage were
higher in the secondary than in the primary prevention
group. Prior ischemic stroke/TIA emerged as an inde-
pendent risk for both events after adjustment for multiple
confounding factors. Third, for prevention of thrombo-
embolism, an INR level of 1.6-2.59 would be optimal
among Japanese NVAF patients in the secondary as well
as in the primary prevention groups.
Efficacy and Safety of Warfarin
Although the use of NOACs is increasing worldwide,18
the current Japanese guidelines14 recommend both war-
farin and NOACs for the prevention of thromboembolism
for patients with NVAF. Warfarin is still used in clinical
practice18 and indicated for NVAF patients who have renal
insufficiency and other comorbidities. Therefore, the present
results would be practically important even in the era
of NOACs.
In the present study, efficacy of warfarin for prevent-
ing thromboembolism was apparent in both the secondary
and primary prevention groups (Fig 2). This salutary effect
of warfarin was evident particularly in patients aged 70
years or older for both the primary and the secondary
prevention of stroke (Fig 3). Although rates of thrombo-
embolism in patients aged younger than 70 years on
warfarin appeared to be lower than in those without war-
farin in both the primary and secondary groups, these
differences were not statistically significant (Fig 3, A). As
the number of patients and events in each group was
small, it could be explained that statistical power was
insufficient when patients were divided into 2 preven-
tion groups and an additional 2 age groups. In our previous
subanalysis on event rates in age groups in patients with
NVAF,19 there was a significant difference in rates of throm-
boembolism between patients with and without warfarin
even in patients aged younger than 70 years. Therefore,
warfarin therapy would be beneficial in preventing throm-
boembolism even in patients aged younger than 70 years.
However, it remains controversial whether warfarin therapy
is really beneficial in younger patients aged younger than
65 years because the difference disappeared in younger
patients when the cutoff age was 65 years.19 A meta-
analysis of 6 randomized controlled studies on the effects
of warfarin in patients with NVAF showed comparable
risk reduction of thromboembolism for primary preven-
tion studies (including several % of patients with prior
ischemic stroke) and a secondary prevention study, al-
though target INR levels differed among the studies.20
The European Atrial Fibrillation Trial 21 was a second-
ary prevention study with 1007 NVAF patients to determine
the efficacy of warfarin and aspirin. The target INR level
was set at 2.5-4.0, and aspirin was given at a dose of
300 mg. Warfarin was effective at preventing thrombo-
embolic events, as compared to aspirin (HR .38, P < .001)
and placebo (HR .34, P < .001). However, warfarin was
associated with major hemorrhage more frequently
(2.8%/year), as compared with aspirin (.9%/year) and
placebo (.7%/year). In our secondary prevention group,
somewhat different results were observed; overall, war-
farin was associated with a significantly lower incidence
of thromboembolic events (2.2%/2 years), but not with
a higher incidence of major hemorrhage (3.2%/2 years).
This could be attributed to lower INR levels in the sec-
ondary prevention group in the present study (1.97 ± .48).
Target Anticoagulation Intensity for Secondary
Prevention
Current guidelines in Western countries for manage-
ment of patients with AF recommend the same INR
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Table 7. Incidence rates of events in each age group and each INR level
Events Nonwarfarin
Warfarin
P value**All
INR level*
<1.6 1.6-1.99 2.0-2.59 2.6-2.99 ≥3.0
Primary prevention group
<70 years
Number of patients 592 2398 499 855 810 140 94
Thromboembolism 10 (1.7%) 18 (.8%) 9 (1.8%) 5 (.6%) 1 (.1%) 2 (1.4%) 1 (1.1%) <.001†
Major hemorrhage 6 (1.0%) 28 (1.2%) 4 (.8%) 6 (.7%) 7 (.9%) 6 (4.3%) 5 (5.3%) <.001†
Thromboembolism + major hemorrhage 16 (2.7%) 46 (1.9%) 13 (2.6%) 11 (1.3%) 8 (1.0%) 8 (5.7%) 6 (6.4%) <.001
All-cause death 9 (1.5%) 24 (1.0%) 6 (1.2%) 6 (.7%) 7 (.9%) 3 (2.1%) 2 (2.1%) .420
Cardiovascular death 3 (.5%) 12 (.5%) 2 (.4%) 3 (.4%) 5 (.6%) 2 (1.4%) 0 (.0%) .610
≥70 years
Number of patients 431 2945 694 1043 884 191 133
Thromboembolism 16 (3.7%) 53 (1.8%) 28 (4.0%) 12 (1.2%) 9 (1.0%) 2 (1.0%) 2 (1.5%) .008†
Major hemorrhage 6 (1.4%) 69 (2.3%) 7 (1.0%) 11 (1.1%) 19 (2.1%) 2 (1.0%) 30 (22.6%) .004†
Thromboembolism + major hemorrhage 22 (5.1%) 122 (4.1%) 35 (5.0%) 23 (2.2%) 28 (3.2%) 4 (2.1%) 32 (24.1%) <.001
All-cause death 50 (11.6%) 72 (2.4%) 18 (2.6%) 28 (2.7%) 12 (1.4%) 4 (2.2%) 10 (7.5%) <.001
Cardiovascular death 14 (3.2%) 29 (1.0%) 9 (1.3%) 11 (1.1%) 5 (.6%) 0 (.0%) 4 (3.0%) <.001
Secondary prevention group
<70 years
Number of patients 27 339 72 119 116 21 11
Thromboembolism 2 (7.4%) 5 (1.5%) 3 (4.2%) 1 (.8%) 1 (.9%) 0 (.0%) 0 (.0%) .014†
Major hemorrhage 0 (.0%) 8 (2.4%) 4 (5.6%) 1 (.8%) 2 (1.7%) 1 (4.8%) 0 (.0%) .653†
Thromboembolism + major hemorrhage 2 (7.4%) 13 (3.8%) 7 (9.7%) 2 (1.7%) 3 (2.6%) 1 (4.8%) 0 (.0%) .013
All-cause death 3 (11.1%) 2 (.6%) 1 (1.4%) 0 (.0%) 1 (.9%) 0 (.0%) 0 (.0%) <.001
Cardiovascular death 1 (3.7%) 0 (.0%) 0 (.0%) 0 (.0%) 0 (.0%) 0 (.0%) 0 (.0%) .028
≥70 years
Number of patients 76 578 124 214 177 33 30
Thromboembolism 7 (9.2%) 15 (2.6%) 8 (6.5%) 5 (2.3%) 1 (.6%) 1 (3.0%) 0 (.0%) <.001†
Major hemorrhage 2 (2.6%) 21 (3.6%) 2 (1.6%) 4 (1.9%) 7 (4.0%) 4 (12.1%) 4 (13.3%) .001†
Thromboembolism + major hemorrhage 9 (11.8%) 36 (6.2%) 10 (8.1%) 9 (4.2%) 8 (4.5%) 5 (15.2%) 4 (13.3%) .028
All-cause death 15 (19.7%) 19 (3.3%) 4 (3.2%) 3 (1.4%) 6 (3.4%) 1 (3.0%) 5 (16.7%) <.001
Cardiovascular death 4 (5.3%) 5 (.9%) 0 (.0%) 2 (.9%) 1 (.6%) 0 (.0%) 2 (6.7%) .003
Abbreviations: INR, international normalized ratio of prothrombin time; TIA, transient ischemic attack.
Data are number of patients (%).
*At the time of events or at the end of follow-up.
**Comparison between nonwarfarin group and 5 INR subgroups in patients receiving warfarin (chi-square test).
†For trend.
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Table 8. Odds ratios for events in each age group and INR subgroup
Events Nonwarfarin (reference)
Warfarin
P value
INR level*
<1.6 1.6-1.99 2.0-2.59 2.6-2.99 ≥3.0
A. Primary prevention group
<70 years
Thromboembolism 1.00 .83 (.32-2.16) .26 (.09-.80) .05 (.01-.43) .60 (.13-2.87) .49 (.06-3.97) .032
Major hemorrhage 1.00 .60 (.16-2.19) .54 (.17-1.72) .65 (.21-2.02) 3.50 (1.07-11.43) 4.04 (1.17-13.96) .002
Thromboembolism + major hemorrhage 1.00 .74 (.34-1.60) .36 (.16-.81) .27 (.11-.66) 1.65 (.67-4.05) 1.86 (.69-4.99) <.001
All-cause death 1.00 .43 (.15-1.26) .28 (.09-.80) .31 (.11-.88) .83 (.21-3.22) .78 (.16-3.91) <.001
Cardiovascular death 1.00 .40 (.06-2.51) .42 (.08-2.19) .67 (.15-2.94) 1.55 (.24-9.95) 0 .070
≥70 years
Thromboembolism 1.00 1.11 (.58-2.14) .31 (.14-.68) .28 (.12-.65) .31 (.07-1.37) .42 (.09-1.88) <.001
Major hemorrhage 1.00 .74 (.24-2.25) .84 (.31-2.33) 1.62 (.63-4.16) .81 (.16-4.09) 21.96 (8.66-35.67) <.001
Thromboembolism + major hemorrhage 1.00 1.02 (.58-1.79) .45 (.25-.83) .64 (.36-1.14) .44 (.15-1.30) 6.24 (3.40-11.45) <.001
All-cause death 1.00 .17 (.09-.30) .21 (.12-.34) .09 (.05-.18) .16 (.06-.47) .51 (.24-1.07) <.001
Cardiovascular death 1.00 .34 (.14-.83) .15 (.15-.77) .16 (.06-.46) 0 .77 (.24-2.49) <.001
B. Secondary prevention group
<70 years
Thromboembolism 1.00 .63 (.09-4.37) .12 (.01-1.51) .12 (.01-1.54) 0 0 .629
Major hemorrhage 1.00 – – – – – –
Thromboembolism + major hemorrhage 1.00 .58 (.29-8.73) .24 (.03-1.85) .36 (.05-2.39) .73 (.06-9.04) 0 .446
All-cause death 1.00 .04 (.00-1.12) 0 .02 (.00-.46) 0 0 .007
Cardiovascular death 1.00 0 0 0 0 0 .313
≥70 years
Thromboembolism 1.00 .78 (.25-2.37) .21 (.08-.91) .06 (.01-.52) .33 (.04-2.92) 0 .033
Major hemorrhage 1.00 .59 (.18-4.50) .64 (.11-3.71) 1.47 (.28-7.61) 4.64 (.77-28.07) 5.79 (.94-33.70) .123
Thromboembolism + major hemorrhage 1.00 .70 (.26-1.87) .34 (.12-.91) .36 (.13-1.02) 1.34 (.40-4.51) 1.29 (.35-4.73) .155
All-cause death 1.00 .12 (.03-.41) .05 (.01-.21) .13 (.04-.38) .15 (.02-1.28) .93 (.27-3.17) <.001
Cardiovascular death 1.00 0 .27 (.04-1.78) .16 (.02-1.60) 0 1.72 (.26-11.50) .015
Abbreviations: INR, international normalized ratio of prothrombin time.
Data are odds ratios (95% confidence interval) adjusted for the components of CHA2DS2-VASc score (congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, vascular
disease [coronary artery disease], age 65-74 years, and female sex) and antiplatelet use, using the nonwarfarin group as a reference.
*At the time of events or at the end of follow-up.
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levels for the primary and secondary prevention of
thromboembolism in NVAF patients with and without
prior ischemic stroke/TIA.22,23 In the Japanese guidelines,14
target INR levels of 1.6-2.6 are recommended for pa-
tients aged 70 years or older; this is based on results of
the secondary prevention study by Yasaka et al10 and the
J-RHYTHM Registry.13 Concentration of D-dimer as an
index of fibrinolytic activity and prothrombin fragment
F1+2 as an index of coagulation activity was not differ-
ent between INR levels of 1.5-1.9 and 2.0 or higher in
Japanese patients with NVAF.24 This indicated that slightly
lower anticoagulation intensities of warfarin could be ef-
fective at inhibiting prothrombotic activity in Japanese
patients with NVAF.
NVAF patients with prior ischemic stroke/TIA are at
higher risk for thromboembolism than those without prior
ischemic events, and therefore anticoagulation therapy is
indicated. One might ask whether higher INR values would
be required for prevention of thromboembolism in the
secondary prevention group as compared to the primary
prevention group, but this was not the case. An INR level
of 1.6-2.59 would be optimal for prevention of throm-
boembolism in the secondary as well as in the primary
prevention group among Japanese NVAF patients.
The frequency of intracranial hemorrhage on warfa-
rin therapy with a target INR level of 2.0-3.0 was 4-fold
higher in Asian than in Caucasian patients.25 Suzuki et al26
also showed that INR levels of 2.27 or higher were as-
sociated with an increased risk of major hemorrhage in
Japanese patients with NVAF. The present results showing
that INR levels of 2.6 or higher were associated with higher
rates of major hemorrhage are consistent with prior
results.25,26
Study Limitations
The present study had several limitations. First, it was
performed in a single country and the subjects were en-
rolled in only 158 institutions in Japan. Because most
participating physicians were cardiologists, the pa-
tients’ clinical backgrounds might not be extrapolated to
a general Japanese patient population with NVAF. There-
fore, generalizing from the present results of this specific
population to individual clinical situations should be done
carefully. Second, although this registry was relatively large,
analyzing a total of 7406 patients with NVAF, the numbers
of patients and events in INR subgroups were small es-
pecially in the secondary prevention group. This might
have reduced the statistical power of the present study.
Third, because the study design was prospective but ob-
servational, antithrombotic treatments with warfarin or
antiplatelet agents were not randomized. Dosage of war-
farin and clinical targets of INR levels for individual
patients were selected at the discretion of treating phy-
sicians. Fourth, 1.5% of patients were lost to follow-up
in the present study, which could have led to the
underreporting of endpoints. Finally, the present study
had been performed before NOACs were approved for
clinical use in Japan. Therefore, the present results should
be interpreted carefully in the era of NOACs.
Conclusions
Both thromboembolism and major hemorrhage oc-
curred more frequently in NVAF patients with prior stroke/
TIA even when TTR was higher as compared with those
without prior stroke/TIA. A history of ischemic stroke/
TIA is an independent risk factor for both events.
Anticoagulation therapy with warfarin was performed fre-
quently for the secondary prevention of stroke in Japan
and could have a reducing effect for thromboembolism.
An INR level of 1.6-2.59 would be optimal for prevent-
ing thromboembolism and for avoiding major hemorrhage
in Japanese NVAF patients for the secondary as well as
primary prevention of thromboembolism.
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